Ironwood Pharmaceuticals Provides Third Quarter 2016 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St futures muted as bond yields resume climb; Walmart drops after results
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Crypto stocks surge as Bitcoin short squeeze hits record $2.7B
- Deere shares climb as fiscal Q3 earnings and revenue top estimates
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Mizuho Securities Raises Price Target on Ironwood Pharma (IRWD) Following 3Q Beat
November 4, 2016 7:38 AM EDTMizuho Securities reiterated a Buy rating on Ironwood Pharmaceuticals (NASDAQ: IRWD), and raised the price target to $20.00 (from $19.00), following the company's 3Q earnings report. IRWD reported revenues of $66.1M and a loss of ($0.18) vs. StreetAccount consensus of $59.8M and ($0.24).
Analyst Irina... More
